Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1 (NDUFA1) is a small accessory subunit of mitochondrial complex I, located within the inner mitochondrial membrane. While not directly involved in catalysis, it facilitates complex assembly, stabilizes structural organization, helps anchor complex I, and contributes indirectly to proton translocation during electron transfer from NADH to ubiquinone. Dysfunction or mutation of NDUFA1 can impair ATP production, increase ROS, and is causative in rare mitochondrial disorders such as complex I deficiency and Leigh syndrome. Complex I activity and associated ROS generation are of clinical importance; numerous drugs and toxins (e.g., metformin, rotenone, paraquat) interact with complex I—sometimes targeting NDUFA1—and carry therapeutic or safety implications.
Inhibitors (Metformin, Rotenone): reduce electron flow through complex I, decrease ATP synthesis, increase mitochondrial ROS generation, trigger apoptosis in high doses/contexts
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1 (NDUFA1).